Analysts think CNTB stock price could increase by 207%
Dec 13, 2025, 12:26 PM
12.45%
What does CNTB do
Connect Biopharma Holdings, based in San Diego, develops therapies for T cell-driven inflammatory diseases and went public on March 19, 2021. Its lead candidates include rademikibart for atopic dermatitis and asthma, and icanbelimod for ulcerative colitis.
7 analysts think CNTB stock price will increase by 207.23%. The current median analyst target is $7.65 compared to a current stock price of $2.49. The lowest analysts target is $6.06 and the highest analyst target is $10.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.